Key information made simple
This study is looking at care and outcomes for people with depression, psychosis, or bipolarity. Taking part may give some people access to Valbenazine, but direct benefit is not guaranteed.
RecruitingNCT07105111
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
This study is recruiting. It focuses on schizophrenia and currently lists participation information in the United States.
SchizophreniaDrugOver 18 Years
Your next step
The official record suggests in-person participation through a clinic, with sites including Neurocrine Clinical Site in Bryant, Neurocrine Clinical Site in Fountain Valley, and Neurocrine Clinical Site in Orange. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually matching the main diagnosis, while common reasons not to take part include active substance or alcohol problems that could affect the results and other factors that could make participation unsuitable. This is a later-stage study, which usually means the approach is being followed in broader real-world use.
Key study information
- Official title
- A Phase 4, Open-Label Study to Evaluate the Efficacy of Valbenazine on Clinician- and Patient-Reported Outcomes in Patients With Tardive Dyskinesia (TD) Who Remain Symptomatic While on Deutetrabenazine or After Discontinuing Prior TD Treatment With a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Condition
- Schizophrenia; Schizoaffective Disorder; Bipolar Disorder; Major Depressive Disorder; Tardive Dyskinesia
- Study status
- Recruiting
- Phase
- Phase 4
- Sponsor / lead affiliation
- Neurocrine Biosciences
- Intervention
- Valbenazine
- Location / country
- United States
- Contact
- Neurocrine Medical Information Call Center
- medinfo@neurocrine.com
- Phone
- 1-877-641-3461
- Registry
- ClinicalTrials.gov
Why this study may matter
This study may matter because it is evaluating Valbenazine in a structured research setting. For people exploring bipolarity research, clear information about the goal, status, contacts, and official source can support better questions before any decision.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Registry reference
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
Open source recordAsk HopeStage to review this study with me
This form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.
Study reference: NCT07105111. We only ask for your email here. HopeStage can help you review the study, but this is not a medical eligibility decision.
For you
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in United States.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Things to check before joining
- Sponsor
- Neurocrine Biosciences
- Sponsor type
- Biotech company
- Main activity
- medication or study treatment
- Intervention
- Valbenazine
- Time commitment
- long follow-up or multiple visits
- Study phase
- Phase 4
- Enrollment
- Not available
- Recruitment status
- Recruiting
- Source
- Official registry link
Questions about this study
What is A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor?
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.
Who is behind this study, and what type of sponsor is it?
This study is sponsored by Neurocrine Biosciences, a biotech company. Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company. The sponsor is based in the United States. Sponsor website: https://www.neurocrine.com. You can verify the sponsor and study responsibility in the official registry record.
What does participation involve, what phase is it, and what should I ask about safety?
This study may involve medication or study treatment, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is Phase 4. Earlier-phase studies are often more focused on safety, dose, or feasibility, while later-phase studies usually involve more participants and more information about the intervention. The official source record gives the most accurate details. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Where can I verify the study details?
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.